Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

ge for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com

This press release may contain forward-looking statements, which reflect the Corporation's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    BioMS Medical Corp.
    (A Development Stage Corporation)
    Consolidated Balance Sheet
    December 31, 2008 and 2007
    -------------------------------------------------------------------------

    (expressed in thousands of Canadian dollars)

                                                             2008       2007
                                                                $          $

'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 6, 2015 ... von der Assistance Publique - Hôpitaux de ... ist eine französische, gemeinschaftliche, randomisierte Kontrollstudie für ... wurden. Verglichen werden Patienten mit fortgeschrittenem hepatozellulärem ... oder Sorafenib behandelt wurden. Die Ergebnisse werden ...
(Date:3/5/2015)... --  HX360 today announced that sixteen companies have ... Challenge competition. These companies, selected from a field ... one of four finalists to present their solutions live ... venture capitalists during the Innovation Challenge event. ... 2015 HIMSS Annual Conference & Exhibition, McCormick Place in ...
(Date:3/5/2015)... 05, 2015 BioPlus Specialty Pharmacy (BioPlus) ... of Vice President of Managed Care. In this role, ... one of the nation’s leading specialty pharmacies. , Damm, ... years of specialty pharmacy and biotech experience to his ... Pharmaceuticals, Vertex Pharmaceuticals, and Pfizer. Prior to working in ...
(Date:3/5/2015)... and TORONTO , March ... APS), a clinical-stage company developing new therapeutics and molecular ... announced that William G. Rice , Ph.D., Chairman, ... upcoming 27th Annual ROTH Conference on Tuesday, March 10 ... Ritz Carlton, Laguna Niguel, CA. ...
Breaking Biology Technology:Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3
... that Dr. Robert Harman, DVM, MPVM, CEO of Vet-Stem, ... of Action" at the Annual Research Symposium of the ... October 21, 2010.   (Logo: http://photos.prnewswire.com/prnh/20060425/VETSTEMLOGO ... Dr. Harman has presented at more than 40 veterinary ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, ... for its CYT387 JAK1/JAK2 inhibitor program demonstrating that ... profile which may provide significant clinical advantages. CYT387 ... clinical study at Mayo Clinic in patients with ...
... RALEIGH, NC and QUEBEC CITY, Oct. 1 /PRNewswire-FirstCall/ ... of Medicago Inc. (TSX: MDG), a biotechnology company ... based on proprietary manufacturing technologies and Virus-Like Particles ... U.S. Senator Kay Hagan (D-NC) and U.S. Congressman ...
Cached Biology Technology:Vet-Stem CEO to Present Invited Talk at Veterinary Surgery Meeting 2YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 2YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 3Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 2Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 3
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... N.C. , Feb. 5, 2015  Marken is ... logistics company and has launched a new marketing campaign ... Logistics Organization (CLO).  The new campaign focuses on ... patient, protocol and shipments. The first headline ... , aligns Marken,s priorities with its client,s priorities. Marken ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces the ... as part of its 2015 marketing and branding initiatives ... new consumer website for Wocketwallet.com earlier this month. ... said, "Our new corporate website naturally showcases our premiere ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... time, researchers have inhibited the development of epilepsy after a ... signaling pathways in the brain, neurology researchers found that they ... , "We have shown that there is a window ... that epilepsy will develop," said one of the lead researchers, ...
... Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ... that a single drug can rebuild damaged muscle in ... two human forms of muscular dystrophy. This advance, which ... from a research collaboration that began several years ago ...
... What is more, a newt can also completely repair damage ... Heart and Lung Research in Bad Nauheim have now started ... regenerate and have discovered the remarkable plasticity of newt heart ... this ability, the findings could contribute to new cell therapies ...
Cached Biology News:Gene therapy inhibits epilepsy in animals 2Scientists show drug can counteract muscular dystrophy in mice 2Newts which regrow their hearts 2
... DNA Polymerase I from ... DNA polymerase. The enzyme also ... activities.1 The 5'?3' exonuclease activity ... nicks and gaps in the ...
... E. coli strain containing an overproducing clone ... Reverse Transcriptase catalyzes the polymerization of DNA ... Full-length copies of large mRNAs, >10 kb, ... a much lower RNase H activity than ...
... catalyzes the template-directed polymerization of nucleotides into ... Polymerase I possesses a 3?5 exonuclease activity ... rate during DNA replication, and also contains ... enzyme to replace nucleotides in the growing ...
Request Info...
Biology Products: